Seladelpar: New hope for patients with primary biliary cholangitis.
Med
; 5(5): 377-379, 2024 May 10.
Article
in En
| MEDLINE
| ID: mdl-38733969
ABSTRACT
The study by Hirschfield et al.1 demonstrated safety profile and clinically significant effectiveness of the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar in patients with primary biliary cholangitis, highlighting its plausible use as a second-line treatment to reduce disease activity and pruritus.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pruritus
/
Liver Cirrhosis, Biliary
Limits:
Humans
Language:
En
Journal:
Med
Year:
2024
Document type:
Article
Affiliation country:
España